A multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study of East Indian Sandalwood Oil (EISO) for the treatment of mild to moderate atopic dermatitis (AD).

Trial Profile

A multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study of East Indian Sandalwood Oil (EISO) for the treatment of mild to moderate atopic dermatitis (AD).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Santalum album (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 May 2017 Status changed from not yet recruiting to recruiting, according to a Santalis Pharmaceuticals media release.
    • 21 Nov 2016 New trial record
    • 03 Nov 2016 According to Santalis Pharmaceuticals media release, company has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top